IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.

IGM Biosciences (IGMS) is slashing its workforce by 73% and discontinuing development of two of its lead drug candidates in ...

Royal Bank of Canada lowered shares of IGM Biosciences (NASDAQ:IGMS – Free Report) from an outperform rating to a sector ...

Wedbush restated their neutral rating on shares of IGM Biosciences (NASDAQ:IGMS – Free Report) in a report issued on Friday ...

IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell ...

The company is reducing its workforce by 73% and evaluating strategic alternatives to preserve shareholder value.

Fintel reports that on January 10, 2025, Jefferies downgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from Buy to ...

Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...

The biotech will stop developing two drugs and lay off nearly three-quarters of its staff after its lead therapy wasn’t as ...

Just two weeks into 2025, January is proving why it’s earned a reputation as the worst month for layoffs. | Just two weeks ...

IGM Biosciences (IGMS – Research Report) received a Hold rating and a $2.00 price target from Jefferies analyst Roger Song today. The company’s ...